cinnarizine and Brain-Injuries

cinnarizine has been researched along with Brain-Injuries* in 2 studies

Trials

1 trial(s) available for cinnarizine and Brain-Injuries

ArticleYear
Characteristics of the formation of chronic fatigue syndrome and approaches to its treatment in young patients with focal brain damage.
    Neuroscience and behavioral physiology, 2007, Volume: 37, Issue:3

    Chronic fatigue is among the manifestations of focal brain lesions. It is most often encountered in multiple sclerosis (MS) and patients with the sequelae of traumatic, inflammatory, and vascular brain damage (encephalopathies). The aim of the present work was to study the mechanisms of formation of this syndrome in 50 patients with focal brain lesions of different origins (in the inactive stage) and to assess the possibility of correcting it using the combined agent Fezam (2 capsules t.i.d. for one month), which contains piracetam and cinarrizine. In patients with encephalopathies, chronic fatigue syndrome was directly associated with the severity of depression. Patients with MS showed changes in the value-sense sphere. Neuropsychological testing showed that the psychological and personality components played a greater role in the origins of chronic fatigue in patients with encephalopathies than in those with MS. Fezam significantly decreased the severity of chronic fatigue, particularly in patients with MS; in the second group (non-MS patients) this was accompanied by a decrease in the severity of depression. Mild side effects (in six patients--12%) consisted generally of sleep disturbances. These results indicate that Fezam should be used in the treatment of chronic fatigue in patients with focal brain lesions; in encephalopathies it should be combined with psychoactive agents.

    Topics: Adult; Brain Injuries; Calcium Channel Blockers; Cinnarizine; Drug Therapy, Combination; Fatigue Syndrome, Chronic; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Piracetam; Severity of Illness Index

2007

Other Studies

1 other study(ies) available for cinnarizine and Brain-Injuries

ArticleYear
Cinnarizine dissolving microneedles against microwave-induced brain injury.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 155

    Microwave is commonly used in the life, manufacturing and military fields, which may induce body injuries. Brain is the major target organ of microwave radiation and microwave-induced brain injury (MIBI) can lead to insomnia, dreaminess, and a decline in learning and memory. However, there is no clinical medications are available currently. Calcium channel blockers may protect the brain tissue from microwave but most of them cannot enter the brain. Here, we selected a calcium channel blocker-cinnarizine to prepare its dissolving microneedles (MNs) for the therapy of MIBI. The cinnarizine MNs was composed of polyvinyl pyrrolidone (PVP) K90 as the tip, the photopolymerized PVP as the base and the drug, which owned high mechanical strength, leading to easily piecing the skin on the neck and high drug release in vivo. The cinnarizine MNs markedly improved the recovery of spatial memory and spontaneous exploratory behavior of the rats after microwave radiation by inhibiting the expression of calcineurin and calpain-1. The dissolving MN technique is a promising method to improve drugs into the body and perform the anti-microwave radiation action.

    Topics: Administration, Cutaneous; Animals; Brain Injuries; Calcineurin; Calcium Channel Blockers; Calpain; Cinnarizine; Drug Delivery Systems; Needles; Polyvinyls; Povidone; Rats

2022